Advertisement

Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support

  • Claudio CerchioneEmail author
  • Amalia De Renzo
  • Davide Nappi
  • Maria Di Perna
  • Roberta Della Pepa
  • Novella Pugliese
  • Lucio Catalano
  • Fabrizio Pane
  • Marco Picardi
Letter to the Editor
  • 45 Downloads

Dear editor,

We would like to thank Osamu Imataki and his colleagues [1] for their comments on our recent original article about a real-life experience on the use of pegfilgrastim in primary prophylaxis of febrile neutropenia (FN) for patients with non-Hodgkin lymphoma (NHL) undergoing bendamustine plus rituximab (BR) treatment [2]. Their case report is an example of effectiveness of secondary prophylaxis with G-CSF in a setting of advanced mantle cell lymphoma of an elderly patient (82-year-old) who underwent BR [1]. The authors want to highlight how BR could cause prolonged neutropenia, especially during the following courses of therapy, rather than the initial; therefore, a secondary G-CSF prophylaxis is probably advocated as more properly indicated. There is still lack of data regarding the efficacy of a primary or secondary prophylaxis with G-CSF in BR for patients with NHL. However, our real-life experience suggests that, in a primary prophylactic setting, pegfilgrastim seems to...

Notes

References

  1. 1.
    Imataki O, Uchida S, Yokokura S, Uemura M, Kadowaki N (2018) Bendamustine and G-CSF support. Support Care CancerGoogle Scholar
  2. 2.
    Cerchione C, De Renzo A, Di Perna M et al (2017) Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer 25(3):839–845CrossRefGoogle Scholar
  3. 3.
    Balducci L, Repetto L (2004) Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer 100(1):6–11CrossRefGoogle Scholar
  4. 4.
    Sosa R, Li S, Molony JT, Liu J, Stryker S, Collins AJ (2017) Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. Support Care Cancer 25(10):3123–3132CrossRefGoogle Scholar
  5. 5.
    Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M (2018) Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study. Oncologist 23(4):454–460CrossRefGoogle Scholar
  6. 6.
    Cerchione C, Catalano L, Pareto AE et al (2017) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Support Care Cancer 23(2):301–302CrossRefGoogle Scholar
  7. 7.
    Cerchione C, Catalano L, Peluso I, Nappi D, di Perna M, Salvatore D, Migliaccio I, Picardi M, Pane F (2016) Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. Support Care Cancer 24(12):4835–4837CrossRefGoogle Scholar
  8. 8.
    Cerchione C, Nappi D, Di Perna M et al (2017) A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide. Clin Case Rep 5(4):505–507CrossRefGoogle Scholar
  9. 9.
    Cerchione C, Nappi D, Di Perna M et al (2016) Retreatment with bendamustine-bortezomib-dexamethasone in a patient with relapsed/refractory multiple myeloma. Case Rep Hematol 2016:6745286Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of HematologyIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori – IRCCSMeldolaItaly
  2. 2.Hematology – Department of Clinical Medicine and SurgeryAzienda Ospedaliera Universitaria Federico IINaplesItaly

Personalised recommendations